This review of preliminary evidence concluded that there was no compelling baseline data for or against the use of lowdose computed tomography in screening for lung cancer; final results of the trials should improve understanding of the effectiveness of such screening. These cautious conclusions reflected the findings of the review and may be regarded as reliable.
Participants in included trials had average ages between 50 and 60 years (range 49 to 80 years), with an average smoking history of 20 to 30 pack-years; all trials enrolled volunteers. Half of included trials used chest x-rays in the control group; the other trials used no screening. The collimation beam of low-dose CT scans varied from 0.6 to 5mm, as did the use of positron emission tomography and fine-needle aspiration work-ups of nodules detected. Two reviewers independently selected the studies for inclusion in the review, with disagreements resolved by a third reviewer.
Assessment of study quality
Two reviewers independently assessed the validity of the included trials using the US Preventative Services Task Force guidelines and the Cochrane Collaboration's tool for the assessment of bias assessing generalisability, sample size, dropouts, reproducibility and statistical methodology. Disagreements were resolved by a third reviewer.
Data extraction
Data were extracted to permit the calculation of event rates and odds ratios (OR) with 95% confidence intervals (CI).
Two independent reviewers carried out the data abstraction.
Methods of synthesis
Trials were combined in random-effects meta-analyses; pooled odds ratios and event rates, with 95% confidence intervals, were calculated.
A subgroup analysis of trials using chest x-ray in the control arm was conducted. 
Results of the review
Six RCTs were included in the review (n=14,055 patients), including 7,078 patients in the low-dose CT groups and 6,977 in the control groups. Sample sizes ranged from 190 to 4,104 patients. Drop-out rates ranged from 0 to 21%.
The detection of stage 1 non-small cell lung cancer was statistically significantly higher in the low-dose CT groups than in the control groups (OR 3.91, 95% CI 2.05 to 7.43; six RCTs), as was the detection of any non-small cell lung cancer (OR 5.51, 95% CI 3.13 to 9.70; six RCTs).
The detection of false-positive nodules was statistically significantly higher in the low-dose CT (OR 3.12, 95% CI 2.62 to 3.72; six RCTs). The odds ratio for rate of thoracotomy for benign lesions was 3.71 (95% CI 3.55 to 3.87; seven comparisons) higher in the low-dose CT groups.
Analysis of the subgroup of three RCTs that used chest x-ray in the control groups did not differ substantially from the results of the main analysis.
The fail safe N was calculated as 14 for the outcome of stage 1 non-small cell lung cancer and 279 for the outcome of thoracotomies for benign lesions.
Authors' conclusions
There was no compelling baseline data from six RCTs in favour of or against the use of low-dose CT screening for lung cancer; the final results of these trials should improve understanding of the effectiveness of such screening
CRD commentary
The review question and inclusion criteria were clear. The authors searched several relevant databases without language restrictions, and made attempts to locate unpublished studies. These factors reduced the chance that relevant studies were omitted or selection biases introduced. The authors reported using methods designed to reduce reviewer bias and error at all stages of the review process.
Appropriate criteria were used to assess trial quality, but there was only limited reporting of the results of this assessment. The synthesis appeared appropriate, although there was limited assessment or exploration of potential heterogeneity.
The authors' cautious conclusions reflected the findings of this review of preliminary evidence and may be regarded as reliable.
